The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study.
about
Recent advances in managing and understanding diabetic nephropathyCurrent strategies for preventing renal dysfunction in patients with heart failure: a heart failure stage approachCardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An updateObesity and kidney protectionOvercoming Challenges With Statin TherapyLowering cholesterol in chronic kidney disease: is it safe and effective?Effect of statins and aspirin alone and in combination on clinical outcome in dyslipidaemic patients with coronary heart disease. A subgroup analysis of the GREACE studyDiagnosis and management of the metabolic syndrome in obesityStatin-associated muscular and renal adverse events: data mining of the public version of the FDA adverse event reporting systemNon-alcoholic fatty liver disease: an emerging driving force in chronic kidney disease.Rosuvastatin protects against podocyte apoptosis in vitroDiabetic Nephropathy: New Risk Factors and Improvements in DiagnosisEffect of single tablet of fixed-dose amlodipine and atorvastatin on blood pressure/lipid control, oxidative stress, and medication adherence in type 2 diabetic patients.Dyslipoproteinemia and impairment of renal function in diabetic kidney disease: an analysis of animal studies, observational studies, and clinical trials.Progression of kidney disease in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin versus usual care: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).Serum lipid profiles, lipid ratios and Chronic Kidney Disease in a Chinese populationEarly postoperative statin therapy is associated with a lower incidence of acute kidney injury after cardiac surgery.Recognition, pathogenesis, and treatment of different stages of nephropathy in patients with type 2 diabetes mellitusDyslipidaemia of obesity, metabolic syndrome and type 2 diabetes mellitus: the case for residual risk reduction after statin treatmentRenoprotective effects of atorvastatin compared with pravastatin on progression of early diabetic nephropathy.Preventing Cardio-renal Syndrome Rather than Treating It: Could Statins Play A Role?Relation of improvement in estimated glomerular filtration rate with atorvastatin to reductions in hospitalizations for heart failure (from the Treating to New Targets [TNT] study).IMproving the imPlemEntation of cuRrent guidelines for the mAnagement of major coronary hearT disease rIsk factors by multifactorial interVEntion. The IMPERATIVE renal analysis.Is there a role for hypolipidaemic drug therapy in the prevention or treatment of microvascular complications of diabetes?Effects of Omega-3 Fatty Acid Supplementation on Diabetic Nephropathy Progression in Patients with Diabetes and Hypertriglyceridemia.Effects of statins on cardiorenal syndrome.Treatment of dyslipidemia in the elderly.Matrix metalloproteinases and diabetic vascular complications.Dyslipidemia and lipid-lowering therapy in the elderly.Secondary prevention of ischemic cerebrovascular disease. What is the evidence?Patient with hypertriglyceridemia, type 2 diabetes, and chronic kidney disease treated with atorvastatin and omega-3 Fatty Acid ethyl estersEffects of pitavastatin add-on therapy on chronic kidney disease with albuminuria and dyslipidemiaStatins for renal patients: a fiddler on the roof?Statins: another class of antihypertensive agents?Statin therapy in patients with chronic kidney disease: to use or not to use.Drug insight: thiazolidinediones and diabetic nephropathy--relevance to renoprotection.Drug insight: Immunomodulatory effects of statins--potential benefits for renal patients?Non-low-density lipoprotein cholesterol-associated actions of ezetimibe: an overview.Effects of Atorvastatin Dose and Concomitant Use of Angiotensin-Converting Enzyme Inhibitors on Renal Function Changes over Time in Patients with Stable Coronary Artery Disease: A Prospective Observational Study.The role of established and emerging risk factors in peripheral vascular graft occlusion.
P2860
Q26745900-BE768AAA-991C-4939-A34D-5AE0CFBC4A99Q26822842-E5C5C49A-7303-4C09-9175-D0CA3ABE0A54Q26997059-57E56417-5139-4AC9-8A7B-149A0EBB43BEQ27005818-231C5A10-6596-428C-A020-A84894EF6754Q28073319-EA867340-4BDC-4750-B70F-E827EE3B9A70Q28083502-45CFBD4F-15F4-4DD4-9C70-5879D7A27542Q28174014-88650F5A-6716-417A-83DD-CC6F288B0043Q28192856-6746EBBA-1860-4980-9697-AFFB859FFB94Q28478481-66F6427F-07F2-4741-B365-97E8EFD795C6Q30235846-98B48DBF-39A4-4D62-A949-B25FD4D5B6BBQ33372307-93AECB93-819D-4184-B1F3-D20DBF2E0ADEQ33583018-755E4AA0-DB74-4A54-9724-0A7B2B53A8CFQ33655267-0B20D3B0-DC86-4199-8F5D-69538C5ECE12Q33776176-4C22E4D4-E719-43C9-AB02-AC324E35B39FQ33964855-83D3E92F-9AA4-475A-8918-76E14FAD69C1Q34086005-FA1441A9-539A-4538-A1DC-9C5CD751273FQ34354040-CD3E8DC3-41AA-41B8-9687-B791609B6885Q34887952-F1E7BD0C-AA52-4590-8EBA-A099DABAAA2FQ35029623-A1AA9D96-49EF-4ACB-8DA5-9BCEE2FC3C62Q35571854-5D95930C-FE3F-4EE1-9854-CAD7FE2ED36AQ35622817-E3846E01-BF0B-4B17-B417-2337F4D58185Q35679895-8DA93821-C283-47A4-917A-9467C4CC29FDQ35691372-D2437743-9A9D-4D8A-A502-1D09F563FCF0Q35871962-9F411BF2-9B6F-4CBF-9D21-454C8E4FAEB5Q36005146-1283D0C4-B8B4-4AF3-B1F7-B53CC6846E7AQ36077149-5DBCEAFF-0052-420F-BFB2-88F509620E06Q36077229-5AFF1B24-78F8-46F0-97CD-BCF42BE01D46Q36081593-28532A42-3F5E-447A-9517-46D5D76B77C1Q36124897-5E971BA2-247D-4A8C-AA53-2B88C533885CQ36271814-B51C44AD-1E42-4C63-A5E1-D3CB9121860DQ36310496-DB7CB4EA-DA48-4DBC-98F9-B7680ACB1EDCQ36357758-1190CB4D-1684-4C36-ACAF-FD0B021377A9Q36361057-F5BBB73F-8FA9-4687-A491-00FF311E8AF8Q36411099-B8AEE5C6-7CA2-45DD-960B-4E7E0DAB9412Q36558703-3859A962-3528-4A1D-BF32-AD9F61420D3FQ36577073-62AC1654-D6B8-44B7-B5A6-4D70B71FBBC9Q36577189-68DD9530-BCBF-4C92-8375-25F1AA72E7AAQ36653658-6E5310D9-53E1-488C-A8F7-9C1C65DFEA2AQ36666907-25C19916-AE19-47EA-A6F0-E422812C0E0CQ36808026-0E82F2F6-EB77-4ACF-B9C1-61EDADEEE40F
P2860
The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
The effect of statins versus u ...... ase evaluation (GREACE) study.
@ast
The effect of statins versus u ...... ase evaluation (GREACE) study.
@en
type
label
The effect of statins versus u ...... ase evaluation (GREACE) study.
@ast
The effect of statins versus u ...... ase evaluation (GREACE) study.
@en
prefLabel
The effect of statins versus u ...... ase evaluation (GREACE) study.
@ast
The effect of statins versus u ...... ase evaluation (GREACE) study.
@en
P2093
P2860
P356
P1476
The effect of statins versus u ...... ease evaluation (GREACE) study
@en
P2093
A A Papageorgiou
A N Pehlivanidis
A N Symeonidis
D P Mikhailidis
V I Bouloukos
P2860
P304
P356
10.1136/JCP.2003.012989
P407
P577
2004-07-01T00:00:00Z